Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 20/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.54 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.54 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.54 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.54 |
| ▸ | TLK1 | Q9UKI8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21508528 | 1.00 | AAK1 (1.00) | AAK1CITDAPK3JAK2DAPK1 | |
| SCHEMBL20447051 | 0.91 | AAK1 (0.84) | AAK1 | |
| SCHEMBL21508238 | 0.87 | AAK1 (0.77) | AAK1CITDAPK3JAK2DAPK1 | |
| SCHEMBL21649179 | 0.87 | AAK1 (0.77) | AAK1CITDAPK3JAK2DAPK1 | |
| SCHEMBL28479922 | 0.83 | AAK1 (0.71) | AAK1 | |
| SCHEMBL28491900 | 0.82 | AAK1 (1.00) | AAK1 | |
| SCHEMBL21649260 | 0.82 | AAK1 (1.00) | AAK1 | |
| SCHEMBL20574094 | 0.82 | AAK1 (0.73) | AAK1 | |
| SCHEMBL20574096 | 0.82 | AAK1 (0.73) | AAK1 | |
| SCHEMBL21508479 | 0.81 | AAK1 (1.00) | AAK1MAP2K1HIPK4MKNK2BMP2K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112142655-A | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-12-29 | — | — | CN | claimed |
| CN-108368084-B | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-10-16 | — | — | CN | claimed |
| CN-112142655-A | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-108368084-B | Biaryl kinase inhibitors | 百时美施贵宝公司 | 2020-10-16 | — | — | CN | disclosed |
| US-10544120-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544120-B2 | Biaryl kinase inhibitors | AAK1, CAMKK1, CAMKK2 | AAK1 1/4885CIT 1496/4885DAPK3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.